Quebec’s Over-Centralized Health System is a Cautionary Tale - C.D. Howe Institute

Skip to main contentCrypto NewsOct 21, 2026, 8:12 a.m. EDT2 min read(Nikhilesh De/CoinDesk)SummaryVault12 says exchanges want assurance the SEC won’t later challenge a token’s exit from securities rules before listing it. The firm raised $17.45 million selling VGT in 2018 and says it met or dropped every promise, yet the token has never traded on a centralized exchange. Vault12 wants filings to become conclusive if the SEC doesn’t object within 60 days, a fix it says would give exchanges certainty to list. The issuer of a cryptocurrency token that has never traded on a major exchange has presented an early test of the U. S. Securities and Exchange Commission’s (SEC) proposed safe harbor framework. Crypto wallet backup firm Vault12, backed by Winklevoss Capital and Naval Ravikant, warned that the SEC’s proposed token safe harbor could leave exchanges unwilling to list tokens because of the risk of a later regulatory challenge. The safe harbor is part of the SEC’s Regulation Crypto Assets proposal, issued in August to establish conditions under which a token would no longer be subject to its original investment contract.

One of the most significant anniversaries in human history just passed with no celebration or fanfare: the discovery of penicillin. Almost everyone alive today has grown up in the age of antibiotics, and so it’s easy to forget how world-altering this breakthrough was. Most of us wouldn’t make it to adulthood if it weren’t for the work of Sir Alexander Fleming, who shared the 1945 Nobel Prize in physiology or medicine with Ernst Boris Chain and Howard Walter Florey, but is widely credited for his discovery on Sept. 28, 1928. I came to appreciate this anniversary the hard way, having recently flirted with disaster after disobeying the most common of doctor’s orders when prescribed an antibiotic: Finish all medication unless directed otherwise by your physician. This is advice I will never again ignore. But a few days into a 10-day course of an antibiotic I’d been prescribed for strep throat at the beginning of summer, I decided I’d had enough. The consequences arrived several weeks later. There was a sudden swelling of my feet and a strange rash on my legs and feet. Soon, my calves, too, ballooned.

The US-backed hepatitis B vaccine trial in African newborns that drew global backlash was halted, the lead researcher said on Wednesday. It was “now clear” that the study “will not move forward in Guinea-Bissau”, Frederik Schaltz-Buchholzer, a Danish researcher, wrote on LinkedIn, adding, “we were not given the necessary governmental approval.”The minister of health in Guinea-Bissau, Quinhin Nantote, previously denied that the project would move forward. “This is not even remotely true,” Nantote told the Guardian in Portuguese last week. The study was to be funded with $1.6m from the US Centers for Disease Control and Prevention (CDC), along with another $1.6m from private partners like the Bill Ackman-backed Pershing Square Foundation and the Bluebell Foundation. “The solution is clear here: take the money and vaccinate as many kids as you can,” said Paul Offit, a vaccines expert at the Children’s Hospital of Philadelphia, who sharply criticized the proposed study as unethical. The government of Guinea-Bissau now has control over the researchers’ vaccines, which they apprehended when they searched the offices of the Bandim Health Project on Monday.